M3814 further augmented the expression of the myeloid markers, CD11a and CD14, suggesting that DNA-PK inhibitor could provide two potential benefits in AML therapy: enhance DNR-induced apoptosis as well as myeloid differentiation. This evidence concerns the gene ITGAL and acute myeloid leukemia.